Dr Javed Butler: SGLT2 & Vericiguat Combo

Dr. Javed Butler addresses questions about the use of SGLT2 inhibitors and vericiguat in heart failure management. He asserts there’s no theoretical overlap in mechanisms preventing their combined efficacy. Despite SGLT2 inhibitors reducing risks, substantial residual risks remain, necessitating additional therapies like vericiguat. While clinical trials didn’t test their combination, Dr. Butler believes they’re likely safe together due to minimal effects on blood pressure, kidney function, and potassium levels. However, he advises cautious initiation, especially in older patients or those with low baseline blood pressure, emphasizing close monitoring and individualized care.